Q-omics provides the consensus-scored ZNF847P profile across patient tissues and cancer cell-line models. ZNF847P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF847P is differentially expressed in 9, with the highest sampling consensus in UCEC. Additionally, ZNF847P RNA expression shows 7,597 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, UCEC, and GBM as cancer lineages where ZNF847P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF847P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF847P survival associations across molecular data types. ZNF847P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF847P RNA expression–survival associations across cancer types. High ZNF847P expression shows unfavorable associations in KIRC, UVM, THCA, CESC and KICH, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF847P RNA expression.
This table summarizes ZNF847P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF847P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF847P shows lower tumor expression in PAAD and higher tumor expression in UCEC, BRCA, HNSC, KICH and KIRC. The UCEC box plot shows higher ZNF847P RNA expression in tumor versus normal tissue (log2 FC = +0.225, t-test p < 0.001).
This table shows molecular features associated with ZNF847P in patient tissues and cancer cell lines. In patient samples, ZNF847P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
